Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
- Eisai’s Sleep Inducer Dayvigo Approved in Hong Kong
March 3, 2021
- MSD Files Refractory Cough Medicine in Japan
March 3, 2021
- Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
- Mitsubishi Tanabe Licenses Therapeutic App for Depression to DT Axis
March 3, 2021
- Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
- Comirnaty Label Updated in Japan to Ease Storage Temperature: Pfizer/BioNTech
March 2, 2021
- Ono, PeptiDream Ink License Pact for Peptide Drug Discovery
March 2, 2021
- Kissei Seeks Approval for C5aR Inhibitor Avacopan in Japan
March 2, 2021
- Idorsia Files Japan NDA for Clazosentan
March 2, 2021
- Online Meeting Promotions Rise on Decrease in Face-to-Face Visits, In-Hospital Seminars in December: Intage
March 2, 2021
- Kyowa Kirin, Harvard Form Strategic Research Alliance
March 1, 2021
- Daiichi Sankyo to Divest 11 Off-Patent Brands to Alfresa
March 1, 2021
- Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
- UCB Files Psoriasis Med Bimekizumab for Japan Approval
March 1, 2021
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…